Submit via fax to confirm a patient's coverage options for Privigen.
Stein MR, Nelson RP, Church JA, et al; for the IgPro10 in PID study group. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
Church JA, Borte M, Taki H, et al. Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency.
Leger J-M, De Bleecker JL, Sommer C, et al. Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).